Wednesday, June 10, 2026

pharma · Breast Cancer · Prostate Cancer · UTHR

United Therapeutics Europe

United Therapeutics is a pharma organization headquartered in Silver Spring, USA. It trades on NYSE under ticker UTHR. Primary therapeutic focus areas include Breast Cancer, Prostate Cancer, Pulmonary Arterial Hypertensi

1000 Spring Street, Silver Spring, Maryland 20910, US HQ
1996 Founded
1,443 Employees
Public company Type
UTHR · NYSE Ticker
Company details
Status
Public
HQ
1000 Spring Street, Silver Spring, Maryland 20910, US
Founded
1996
Employees
1,443
Programs
1032
Drugs
612
Patents
3720

Quick answer

United Therapeutics is a pharma organization headquartered in Silver Spring, USA. It trades on NYSE under ticker UTHR. Primary therapeutic focus areas include Breast Cancer, Prostate Cancer, Pulmonary Arterial Hypertension, Malaria, HIV Infections. NovaPharmaNews links 1032 clinical program(s), 8 drug profile(s), and 3720 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (336), phase 3 (199), phase 1 (184).

Company snapshot

United Therapeutics Europe maintains 1032 tracked programs across Breast Cancer, Prostate Cancer, Pulmonary Arterial Hypertension, Malaria, HIV Infections, Pulmonary Hypertension, Parkinson Disease, Lung Cancer, Bladder Cancer, Gulf War Illness, COVID-19, Traumatic Brain Injury. Momentum score: 24/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical trials, patents, SEC fi

  • 12 approved product(s) across US/EU regulatory metadata.
  • 1032 active pipeline program(s) linked via ClinicalTrials.gov.
  • 3720 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for United Therapeutics Europe. Not investment advice.

Recent coverage

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for United Therapeutics Europe.

2 active signals

24 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 1079 30d
  • Nova articles 1 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for United Therapeutics Europe.

  1. Clinical update

    Population Council #323 — Phase 2

  2. Clinical update

    NA_00090926 — Phase 3

  3. Clinical update

    ROR-PH-303 — Phase 3

  4. Clinical update

    ROR-PH-301 — Phase 3

  5. Clinical update

    RIN-PF-305 — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is United Therapeutics Europe?

    United Therapeutics is a pharma organization headquartered in Silver Spring, USA. It trades on NYSE under ticker UTHR. Primary therapeutic focus areas include Breast Cancer, Prostate Cancer, Pulmonary Arterial Hypertension, Malaria, HIV Infections. NovaPharmaNews links 1032 clini

  • Is United Therapeutics Europe publicly traded?

    Yes. United Therapeutics Europe is listed with ticker UTHR on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does United Therapeutics Europe develop or market?

    We link 612 drug profile(s) where United Therapeutics Europe is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/united-therapeutics-corp#company-drugs.

  • What are the latest developments for United Therapeutics Europe?

    In the last 12 months our linked public records show 1032 trial program update(s) and 31 US patent grant(s) tied to this profile.

  • What therapeutic areas does United Therapeutics Europe focus on?

    United Therapeutics Europe focuses on Breast Cancer, Prostate Cancer, Pulmonary Arterial Hypertension based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
384
Oncology
99
Infectious Disease
38
Cardiology
34
Neurology
21
Immunology
3
Related companies